Brief: AIM ImmunoTech Reports Positive Data For Intranasal Ampligen (Rintatolimod)
08/12/2022 14:07
Dec 8 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH REPORTS POSITIVE SAFETY, TOLERABILITY AND
BIOLOGICAL ACTIVITY DATA FOR INTRANASAL AMPLIGEN® (RINTATOLIMOD)
IN HEALTHY SUBJECTS
* AIM IMMUNOTECH INC- INTRANASAL ADMINISTRATION OF AMPLIGEN
DEMONSTRATED TO BE WELL-TOLERATED
Source text for Eikon: ID:nGNE2MXdTW
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential